Medtronic PLC $MDT Shares Purchased by Merit Financial Group LLC

Merit Financial Group LLC increased its stake in shares of Medtronic PLC (NYSE:MDT) by 16.0% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 66,158 shares of the medical technology company’s stock after purchasing an additional 9,123 shares during the period. Merit Financial Group LLC’s holdings in Medtronic were worth $6,301,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in MDT. AXQ Capital LP increased its stake in Medtronic by 25.6% during the 2nd quarter. AXQ Capital LP now owns 9,890 shares of the medical technology company’s stock worth $862,000 after buying an additional 2,013 shares during the period. Legacy Advisory Services LLC acquired a new position in shares of Medtronic in the first quarter worth $541,000. GC Wealth Management RIA LLC increased its position in shares of Medtronic by 20.6% during the second quarter. GC Wealth Management RIA LLC now owns 33,569 shares of the medical technology company’s stock worth $2,926,000 after acquiring an additional 5,734 shares during the period. Verdence Capital Advisors LLC raised its stake in shares of Medtronic by 22.0% in the second quarter. Verdence Capital Advisors LLC now owns 29,396 shares of the medical technology company’s stock valued at $2,562,000 after acquiring an additional 5,296 shares in the last quarter. Finally, World Investment Advisors raised its stake in shares of Medtronic by 1.9% in the second quarter. World Investment Advisors now owns 156,107 shares of the medical technology company’s stock valued at $13,608,000 after acquiring an additional 2,868 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on MDT. Truist Financial lowered their target price on Medtronic from $110.00 to $107.00 and set a “hold” rating for the company in a research note on Thursday, December 18th. Wall Street Zen raised Medtronic from a “hold” rating to a “buy” rating in a research report on Saturday, December 20th. Morgan Stanley raised their target price on shares of Medtronic from $107.00 to $117.00 and gave the company an “overweight” rating in a report on Wednesday, November 19th. Daiwa Capital Markets lifted their price target on shares of Medtronic from $104.00 to $117.00 and gave the stock a “buy” rating in a research note on Tuesday, November 25th. Finally, Royal Bank Of Canada increased their price objective on shares of Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a research report on Wednesday, November 19th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and twelve have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $109.94.

Medtronic Price Performance

MDT stock opened at $96.13 on Friday. The business has a 50 day moving average price of $97.60 and a 200 day moving average price of $93.96. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. The stock has a market cap of $123.24 billion, a price-to-earnings ratio of 25.91, a PEG ratio of 2.53 and a beta of 0.71. Medtronic PLC has a fifty-two week low of $79.38 and a fifty-two week high of $106.33.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The company had revenue of $8.96 billion for the quarter, compared to analysts’ expectations of $8.86 billion. During the same quarter last year, the company earned $1.26 earnings per share. The firm’s revenue for the quarter was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities research analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 16th. Shareholders of record on Friday, December 26th will be issued a dividend of $0.71 per share. The ex-dividend date of this dividend is Friday, December 26th. This represents a $2.84 annualized dividend and a dividend yield of 3.0%. Medtronic’s dividend payout ratio (DPR) is presently 76.55%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).